Regen-Cov and Ronapreve market seen growing on pandemic preparedness and chronic disease burden

The Business Research Company says the Regen-Cov and Ronapreve market will keep expanding through 2035 as governments, health systems and drugmakers lean harder on monoclonal antibodies for COVID-19 and future outbreaks. North America led the market in 2025, while Europe is projected to grow fastest.

Why it matters: - Regen-Cov and Ronapreve remain part of the broader market for COVID-19 antibody therapies, even as demand shifts toward preparedness for future outbreaks and variant-specific treatments. - The market is tied to health-system spending, hospital infusion capacity and government purchasing, which can shape how quickly antibody therapies reach patients.

What happened: - The Business Research Company published a report titled Regen-cov and Ronapreve Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Regen-Cov and Ronapreve market was shaped by the global COVID-19 response and is expected to keep growing through the forecast period. - North America held the largest market share in 2025. - Europe is expected to post the fastest growth during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample is available here. - The full report is available here.

The details: - Regen-Cov and Ronapreve combine casirivimab and imdevimab, two monoclonal antibodies designed to target the SARS-CoV-2 spike protein and block viral entry into human cells. - The therapies have authorization for mild to moderate COVID-19 in high-risk patients and for post-exposure prophylaxis. - The report links historical market growth to widespread COVID-19 infections, emergency authorizations for antibody treatments, hospital infusion infrastructure, government procurement and advances in antiviral biologics. - The report says future growth will be supported by pandemic preparedness, rising demand for biologics that can respond quickly, broader outpatient infusion availability, higher investment in monoclonal antibody technology and therapies adapted to new variants. - The report highlights greater deployment of monoclonal antibodies, wider use of passive immunization, early viral neutralization strategies, more emergency-use biologics and tighter integration of pandemic response treatments as key trends. - The report says increasing infectious disease incidence is a key driver, citing factors such as climate change and globalization that can speed the spread of pathogens. - The report cites November 2024 data from the National Library of Medicine showing COVID-19 cases in England rose 11% week over week, with positivity near 9.6%. - The report says rising healthcare investment will support clinical trials, production scale-up, regulatory approvals and distribution for Regen-Cov and Ronapreve. - The report cites OECD data showing average health spending in member countries was nearly USD 6,000 per capita in 2024, adjusted for purchasing power. - The report says chronic disease growth is another demand driver because conditions such as diabetes, heart disease and asthma can raise the risk of severe COVID-19 outcomes. - The report cites Australian Institute of Health and Welfare data from July 2024 showing chronic diseases accounted for 78% of the fatal health burden.

Between the lines: - The market outlook reflects a shift from emergency pandemic use to a narrower but still relevant role in high-risk care and preparedness planning. - The emphasis on biologics, infusion access and variant response suggests the market depends as much on health-system readiness as on the drugs themselves. - The report’s regional split points to a mature market in North America and a faster-expanding opportunity in Europe.

What's next: - The report expects demand to track future infectious disease pressure, healthcare investment and new variant threats. - Market activity will likely continue to focus on monoclonal antibody deployment, outpatient delivery and emergency-use therapeutics. - The Business Research Company says the 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis.

The bottom line: - Regen-Cov and Ronapreve are no longer just pandemic-era treatments; they are now positioned as part of a longer-term antibody market tied to preparedness, chronic disease risk and health-system spending.